Project Grant R21AI182883
Award Date
7/24/25
Completion Date
6/30/27
Dollars Obligated
$444K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $150,220 to Texas Tech University System to study the magnetic properties of red blood cells and monocytes in sickle cell disease (SCD) patients. The goal is to investigate how the magnetic signature and hemoglobin content of these cells can be used to predict the development of vaso-occlusive crises, the major...
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania provides $179,280 in funding from Sep 1, 2024 to Aug 31, 2026. The project aims to investigate how early life nutritional stress impacts neutrophil development and function, and how this in turn modulates the severity of sickle cell disease. The research will utilize blood samples from sickle cell disease patients as well...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $573,821 to the University of North Carolina at Chapel Hill to conduct research on the role of endothelin-1 (ET-1) signaling in regulating renal iron handling in sickle cell disease. The goal is to elucidate the molecular mechanisms by which ET-1/ETA receptor activation promotes renal iron overload, and to assess the potential of ETA receptor antagonism as...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...